Search research articles
Contact Us
Filters
Showing results (81-90 of 126) with videos related to
Page
of 13
Sort By:
The Lancet. Oncology
|
March 25, 2014
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort
Luca Gianni, Wolfgang Eiermann, Vladimir Semiglazov, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 14, 2014
A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors
Jordi Rodon, Hussein A Tawbi, Anne L Thomas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 19, 2013
AACR Cancer Progress Report 2013
, Charles L Sawyers, Cory Abate-Shen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 20, 2013
Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial
Hatem A Azim, Dominique Agbor-Tarh, Ian Bradbury, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 27, 2014
First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma
Jordi Rodon, Michael A Carducci, Juan M Sepulveda-Sánchez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 10, 2009
Biomarkers Predict p53 Gene Therapy Efficacy in Recurrent Squamous Cell Carcinoma of the Head and Neck
John Nemunaitis, Gary Clayman, Sanjiv S Agarwala, et al.
Cancer
|
March 19, 2013
Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial
Howard A Burris, Fabienne Lebrun, Hope S Rugo, et al.
Journal of the National Cancer Institute
|
February 22, 2013
Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2
Michael Gnant, Jose Baselga, Hope S Rugo, et al.
The Oncologist
|
January 30, 2013
Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience
Otto Metzger-Filho, Evandro de Azambuja, Ian Bradbury, et al.
Science Immunology
|
June 7, 2020
Inhibition of Bruton tyrosine kinase in patients with severe COVID-19
Mark Roschewski, Michail S Lionakis, Jeff P Sharman, et al.
Page
of 13
Search research articles
Search
Showing results (81-90 of 126) with videos related to
Sort By:
Page
of 13
The Lancet. Oncology
|
March 25, 2014
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort
Luca Gianni, Wolfgang Eiermann, Vladimir Semiglazov, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 14, 2014
A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors
Jordi Rodon, Hussein A Tawbi, Anne L Thomas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 19, 2013
AACR Cancer Progress Report 2013
, Charles L Sawyers, Cory Abate-Shen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 20, 2013
Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial
Hatem A Azim, Dominique Agbor-Tarh, Ian Bradbury, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 27, 2014
First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma
Jordi Rodon, Michael A Carducci, Juan M Sepulveda-Sánchez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 10, 2009
Biomarkers Predict p53 Gene Therapy Efficacy in Recurrent Squamous Cell Carcinoma of the Head and Neck
John Nemunaitis, Gary Clayman, Sanjiv S Agarwala, et al.
Cancer
|
March 19, 2013
Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial
Howard A Burris, Fabienne Lebrun, Hope S Rugo, et al.
Journal of the National Cancer Institute
|
February 22, 2013
Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2
Michael Gnant, Jose Baselga, Hope S Rugo, et al.
The Oncologist
|
January 30, 2013
Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience
Otto Metzger-Filho, Evandro de Azambuja, Ian Bradbury, et al.
Science Immunology
|
June 7, 2020
Inhibition of Bruton tyrosine kinase in patients with severe COVID-19
Mark Roschewski, Michail S Lionakis, Jeff P Sharman, et al.
Page
of 13